Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

When Lilly reported strong results from SURMOUNT-1 earlier this year, the drugmaker suggested it may be able to file for approval of tirzepatide in obesity before the end of this year.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to access life-changing weight loss medications.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Lilly now plans to file for approval to add the heart failure indication to the label for tirzepatide, which is already sold as Mounjaro for type 2 diabetes and Zepbound for obesity, later this year.

Mounjaro is a prescription drug used to treat type 2 diabetes in adults. Learn about its possible interactions with supplements, other drugs, alcohol, and more.